Quantification of Hepatitis-B DNA Viral Load in Patients Undergoing Haemodialysis for Chronic Kidney Disease
International Journal of Pharmaceutical Quality Assurance · 30.04.2026 · 17 (04)
DOI: 10.25258/ijpqa.17.4.24 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Pharmaceutical Quality Assurance, online erschienen am 30.04.2026. Verfasst von Tanushree Ghosh und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
Patients with chronic kidney disease (CKD) undergoing haemodialysis are at increased risk of acquiring and transmitting blood-borne infections, particularly Hepatitis B virus (HBV). Monitoring of Hepatitis B DNA viral load is essential for early detection, disease monitoring, and infection control in dialysis units.
Aim
To quantify Hepatitis B virus (HBV) DNA viral load in patients undergoing haemodialysis for chronic kidney disease and to assess the burden of viral replication in this high-risk population. Materials and Methods: This study is designed as a hospital-based cross-sectional observational study conducted in the Department of Nephrology and Dialysis Unit of a tertiary care teaching hospital over a period of one year. The study population includes patients diagnosed with chronic kidney disease who are receiving regular maintenance haemodialysis during the study period. A total of 122 patients undergoing haemodialysis were included as the sample size for analysis.
Results
Among the total 122 patients, vaccination status showed a significant association with HBV DNA positivity. Out of 46 fully vaccinated patients, 3patients (6.5%) were HBV DNA positive. Among 38 partially vaccinated patients, 8 patients (21.1%) were HBV DNA positive. In contrast, among 38 non-vaccinated patients, 16 patients (42.1%) were HBV DNA positive. Overall, 27 patients (22.1%) patients were HBV DNA positive in the study population. The association between vaccination status and HBV DNA positivity was statistically highly significant (p = 0.004) .
Conclusion
HBV DNA viral load monitoring is crucial in haemodialysis patients for early identification of active and occult infections. Routine molecular screening, along with strict infection control measures and vaccination programs, is essential to reduce HBV transmission in dialysis units.
Zitieren
APA
Ghosh, T., Pal, A., & Kundu, P. K. (2026). Quantification of Hepatitis-B DNA Viral Load in Patients Undergoing Haemodialysis for Chronic Kidney Disease. International Journal of Pharmaceutical Quality Assurance, 17(04). https://doi.org/10.25258/ijpqa.17.4.24
Vancouver
Ghosh T, Pal A, Kundu PK. Quantification of Hepatitis-B DNA Viral Load in Patients Undergoing Haemodialysis for Chronic Kidney Disease. International Journal of Pharmaceutical Quality Assurance. 2026;17(04). doi:10.25258/ijpqa.17.4.24
BibTeX
@article{Ghosh2026,
author = {Ghosh, Tanushree and Pal, Arup and Kundu, Prabir Kumar},
title = {Quantification of Hepatitis-B DNA Viral Load in Patients Undergoing Haemodialysis for Chronic Kidney Disease},
journal = {International Journal of Pharmaceutical Quality Assurance},
year = {2026},
volume = {17},
number = {04},
doi = {10.25258/ijpqa.17.4.24}
}
EUVIMED